University life sciences IP and project portfolio review
Challenge:
Alacrita developed techno-commercial development plans for selected top priority projects. The client, King's Commercialisation Institute, convened an expert panel which then selected projects which would benefit most from focussed financial support for work to reach one or more value-creating milestones and thereby progress toward partnering and/or spin-out goals.
Solution:
This assignment was conducted over several months and was composed of three phases:
- IP audit: Using a project characterization template running on a secure web-based platform, we surveyed several hundred principal investigators (PIs) to identify potentially commercializable projects with filed or patentable IP. This encompassed the entire life science research portfolio of the university including therapeutics, biomarkers/diagnostics and medical devices.
- Project prioritization: Our consulting team, comprised of pharma, biotech, diagnostics and medtech industry specialists, analyzed the information received from the PIs and validated it through a combination of internal analysis, external research and telephone interviews.
In order to enable projects to be ranked into priority categories for the next stage of the analysis they were scored according to their:- value in use
- market attractiveness
- developability
- Techno-commercial development plans: We developed development plans for selected top-priority projects. Our client convened an expert panel which selected projects most suited for focused financial support in order to reach one or more value-creating milestones and thereby progress toward partnering and/or spin-out goals.
Related Case Studies
Explore similar engagements and see how we've helped other clients achieve their goals.
Product Development
Gene therapy preclinical, CMC, and regulatory strategy
Challenge: An early-stage biotechnology startup company reached out to Alacrita for critical support of its two lead AAV-delivered gene therapy programs. As a virtual company, the...
Product Development
Interim chief medical officer for antiviral drug company
Challenge A European company developing novel antiviral drugs urgently needed an experienced pharmaceutical physician to work as an interim CMO, as the predecessor was about to...
Product Development
Preclinical development support for a gene therapy
Challenge: A biotech company developing novel gene therapy approaches for in vivo cell trans-differentiation required an AAV gene therapy expert to serve on a scientific advisory...
Product Development
Primary market research and patient segmentation mapping in myelofibrosis
Challenge: A venture-backed US biotech company was developing a preclinical biologic for haematological indications and wished to quantify the commercial opportunity for the...
Interested in Learning More?
Contact us to discuss how we can support your project with similar expertise.